Company intelligence / Profile preview

Sirius Pet Biologics

Singapore/Siglap area, Singaporesiriuspetbiologics.com ↗

Ownership: Private
Development stage: Commercial

Overview

Sirius Pet Biologics has launched 11 SKUs under the FURMENT brand targeting gut, immune, renal, and skin health in pets using proprietary postbiotic formulations. Products are distributed to both retail consumers and veterinary clinics across Singapore and Asia Pacific. No clinical trial data is published; efficacy is based on scientific rationale for microbiome modulation.

Therapeutic areas: GastroenterologyDermatologyImmunologyNephrology
Modalities: PostbioticsProbioticsMicrobial therapy (via microbiome modulation)
Industry: Veterinary

Drug pipeline

1 asset

FURMENT

Commercial

Indications: Pet gut health, Pet renal health, Pet liver health, Pet dermal health, Pet immune health

Partnerships

The Barkery Singapore – distribution partnership for animal welfare group initiatives

Beyond the preview

Go deeper on Sirius Pet Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sirius Pet Biologics.